Oruka Therapeutics, Inc. (ORKA) on Monday reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. The company's shares rose more than 20% in pre-market trading.
In the study, 63.5% of patients treated with ORKA-001 achieved PASI 100 at Week 16, indicating complete skin clearance, with similar results seen on the Investigator's Global Assessment (IGA 0). Further, ORKA-001 was well tolerated, with no serious treatment-emergent adverse events reported.
Oruka said it plans to share longer-term data from the trial, including Week 28 efficacy and 52-week follow-up for some patients, in the second half of 2026. The company is also advancing its Phase 2b EVERLAST-B trial, with results expected in 2027.
"These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response," said Joana Goncalves, MBChB, Chief Medical Officer of Oruka.
Oruka stock closed at $69.03 on Friday, up 1.90%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.